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Patients undergoing radical prostatectomy at our hospital from January 1995 until March 2008 were
subjected to limited lymphadenectomy involving only the obturator nerve lymph node. In contrast to
published reports, of 488 biopsies, we encountered only three cases of lymph node metastasis. Therefore,
starting in April 2008, we conducted a prospective study of limited versus extended lymphadenectomy, the
latter involving the obturator fossa and internal iliac lymph nodes. One hundred patients undergoing
radical prostatectomy from April 2008 until January 2010 were divided into two groups depending on
whether they underwent extended lymphadenectomy (n＝49) or limited lymphadenectomy (n＝51). There
were no signiﬁcant differences in the patient background, estimated blood loss, or operation time between the
two groups. Lymph node metastases were not detected in either group. A signiﬁcantly greater number of
lymph nodes was obtained from the extended lymphadenectomy group (average 14.1) than from the limited
lymphadenectomy group (average 8.3 ; p＜0.01). Complications possibly attributable to lymphadenectomy
included lymphocele in two patients in the limited group and one patient in the extended group. Extended
lymphadenectomy was determined to be a safe procedure that provides the pathologist with a large sample
size. None of the patients in either group harbored a detectable lymph node metastasis.
(Hinyokika Kiyo 57 : 359-362, 2011)
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Table 1. Patients characteristics
限局群 拡大群 p value
平均年齢 (range) 67.3（53-75) 66.0（54-75) p＝0.293*
平均術前 PSA 値 (range) 9.9 ng/ml (1.32-39.5) 9.4 ng/ml (0.9-31.9) p＝0.755*
平均観察期間 (range) 357日（57-651) 328日（30-670) p＝0.409*
生検 Gleason score GS≦7 36, GS≧8 15 GS≦7 35, GS≧8 14 p＝0.926**
cT stage cT1c 34, cT2 17 cT1c 39, cT2 10 p＝0.146**
リスク分類 (D’Amico) Low 10, Intermediate 23, High 18 Low 11, Intermediate 21, High 17 p＝0.938**
全摘標本 Gleason score GS≦7 33, GS≧8 18 GS≦7 36, GS≧8 13 p＝0.344**
pT stage pT2 44, pT3 7 pT2 44, pT3 5 p＝0.588**













○4 術後経過，PSA 再発の有無 (PSA 再発は PSA 0.2
ng/ml 以上と定義した）について検討した．統計学的
処理は，患者背景，郭清リンパ節数，周術期成績の群
間比較に unpaired t-test および chi square test を，PSA
再発率の算定には Kaplan-Meier 法を用い，有意差の





Gleason score，cT stage，術前リスク分類 (D’Amico），
全摘標本 Gleason score，pT stage いずれの項目も両群
間に有意差を認めなかった．
2．郭清リンパ節数，リンパ節転移の有無 (Table 2)
Table 3. Operation outcome and complications
限局群 拡大群 p value
平均手術時間 (range) 154分（102-218) 161分（107-258) p＝0.257*
平均出血量 (range) 901 ml（230-3,790) 1,061 ml（334-4,170) p＝0.275*
同種血輸血 あり 3例 あり 2例




Table 2. The number of dissected nodes and
presence or absence of positive nodes
限局群 拡大群 p value
平均郭清リンパ節数
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Fig. 1. Postoperative PSA-free rate.











4．術後経過，PSA 再発の有無 (Fig. 1)
限局群で51例中21例（41.2％）に，また拡大群で49
例中15例（30.6％）に切除断端陽性症例を認めた．
PSA 再発は，限局群で観察期間に 7例認め，PSA 非
再発率は 2 年76.6％であった．拡大群では，PSA 再
発を 2例認め，PSA 非再発率は 2年86.5％であった．
両群間で PSA 再発に有意差を認めなかった (p＝
0.147）．
両群合わせた PSA 再発症例 9例のうち 8例が cT2
で，これらの術前平均 PSA は 22.56 ng/ml (4.83∼
39.45 ng/ml) と高かった．また病理学的病期は pT2
が 6 例，pT3a が 1 例，pT3b が 2 例であった．
Gleason socre は全例 7 以上で，うち 5 例が Gleason









































PSA平均値は 59.9 ng/ml と今回のわれわれの検討に








いう．当科での検討では，治療前 PSA 値≧20 ng/ml




ずれも治療前 PSA ≧20 ng/ml かつ生検 Gleason score
≧8 であった．逆に低リスク前立腺癌 (cT2 以下かつ
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